Replies to post #3884 on Momenta Pharmaceuticals, Inc. (MNTA)

[Rocky3]

I think that I was wrong to say that MNTA thinks that there are current undisclosed applications. But it was very clear that MNTA does its planning based upon the fact that an application could be approved anytime. And it is clear that it thinks that the market is too big not to be attractive to a wide range of competitors. And that no one will know about approvals ahead of time since that applications will be under paragraph 3.

You may think that no one else has the capacity to get approval, but that is not how MNTA is doing its financial planning. At least that is how it presented itself very clearly at the annual meeting. Maybe it was all for show, but it was a matter of signifant emphasis (especially in talking about the need for novel drugs in its portofolio). Wheeler said several times that generic competition is always a concern. Again, it might have been to offset the Palo Alto demand for share price support, but it was clearly said to be a concern long term.